# US 2024/0197695 A1 · Compound for prevention or treatment of kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197695 A1
- Document ID: US20240197695A1
- Status: Published application
- Kind: A1
- Application number: 18/285,820
- Filed: 2022-03-31
- Published: 2024-06-20
- Earliest claimed: 2021-04-06
- Assignees: Oncocross Co., Ltd.
- Applicants: Oncocross Co.,Ltd
- Inventors: Yi Rang KIM
- Web page: https://patentgrep.com/patent/US20240197695A1

## CPC

- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present disclosure, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one of the present disclosure palliates clinical symptoms and alleviates renal failure and renal injury through reduction of blood glucose levels and insulin resistance in diabetic nephrosis animal models. Thus, the compound may be advantageously applied to a use for preventing or treating kidney diseases, especially diabetic renal diseases.

## Claims

### Claim at position 1

1-14. (canceled).

### Claim 15

A method for preventing or treating a kidney disease, comprising administering to a subject in need thereof (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one is a compound having a structure of Chemical Formula 1 below:

### Claim 17 (depends on 15)

The method according to claim 15, wherein the kidney disease comprises one or more selected from the group consisting of acute kidney injury, end-stage kidney disease (ESKD), renal failure, systemic lupus erythematosus, diabetic renal disease (DN), IgA nephritis (IgAN), HIV-related nephropathy, chronic kidney disease, focal segmental glomerulosclerosis (FSGS), minimal change nephrotic syndrome (MCD), and xanthine oxidase deficiency.

### Claim 18 (depends on 15)

The method according to claim 15, wherein the kidney disease is Type 2 diabetic renal disease (diabetic nephropathy).

### Claim 19 (depends on 15)

The method according to claim 15, wherein subject requires inhibiting apoptosis of the renal medulla.

### Claim 20 (depends on 15)

The method according to claim 15, wherein the subject requires inhibiting calcification of the renal medulla.

### Claim 21 (depends on 15)

The method according to claim 15, wherein the method further comprises administering cromolyn or a pharmaceutically acceptable salt thereof.
